Citation Impact
Citing Papers
Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
2011
DNA Damage–Specific Control of Cell Death by Cryptochrome in p53-Mutant Ras–Transformed Cells
2012 StandoutNobel
Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
2010
LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1
2016 Standout
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
2009
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
2010
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Targeting microbial biofilms: current and prospective therapeutic strategies
2017 Standout
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
2015
Ischemia and reperfusion—from mechanism to translation
2011 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Combined modality therapy with TRAIL or agonistic death receptor antibodies
2011
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
2004
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2014
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
2009
Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells
2012
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”
2015
Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
2009
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2013
Antiplatelet Drugs
2011
PEGylated Interferon Displays Differences in Plasma Clearance and Bioavailability Between Male and Female Mice and Between Female Immunocompetent C57Bl/6J and Athymic Nude Mice
2015
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Antibody therapy of cancer
2012 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine Uptake
2001
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
2011
Targeting the apoptosis pathway in hematologic malignancies
2013
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
2003
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Interleukin-6 Contributes to Mcl-1 Up-regulation and TRAIL Resistance via an Akt-Signaling Pathway in Cholangiocarcinoma Cells
2005
Resting Heart Rate in Cardiovascular Disease
2007 Standout
Cell Death
2009
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
2004
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis
2002
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Targeting Apoptosis Pathways in Cancer Therapy
2005
Activation of apoptosis signalling pathways by reactive oxygen species
2016 Standout
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
2009
TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
2009
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
2010
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues
2003
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
2009
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
2008
The TRAIL apoptotic pathway in cancer onset, progression and therapy
2008
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
2010
Gender differences in arrhythmias
2002
Immunogenic anti-cancer chemotherapy as an emerging concept
2008
TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer
2015
The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors
2009 Standout
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
2016
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Towards novel paradigms for cancer therapy
2010
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer
2013
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
2011 Standout
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
2015 Standout
Apoptosis: A Target for Anticancer Therapy
2018 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
2016
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
2010
Diabetes and Cancer
2010 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture
2011 StandoutNobel
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
2012
The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment
2007
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
2008
Circadian Clock, Cancer, and Chemotherapy
2014 StandoutNobel
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
2008
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
2013
Telomere-Homologous G-Rich Oligonucleotides Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and Apoptosis
2013
Drug Resistance in Cancer: An Overview
2014 Standout
Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer
2011
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Mortality in Patients After a Recent Myocardial Infarction
2004
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of A. Corey being referenced
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
2007
Population Pharmacokinetics and Exposure‐Response of Albinterferon Alfa‐2b
2011
Effect of Multiple Cilostazol Doses on Single Dose Lovastatin Pharmacokinetics in Healthy Volunteers
1999
Azimilide Dihydrochloride, a Novel Antiarrhythmic Agent
1998
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies
2005
A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin
2008
Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1
2007
30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors
2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
2004
Bioavailability of Single and Multiple Doses of Enteric-Coated Mesalamine and Sulphasalazine
1990
HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial
2005
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors
2004
208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial
2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
2004
A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
2008
Bacillus anthracis Protective Antigen Kinetics in Inhalation Spore-Challenged Untreated or Levofloxacin/ Raxibacumab-Treated New Zealand White Rabbits
2013
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study
2006
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors
2004
197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer
2004